CHRS - Coherus BioSciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.55
-0.16 (-1.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.71
Open14.72
Bid0.00 x 3000
Ask0.00 x 1100
Day's Range14.38 - 14.85
52 Week Range8.32 - 20.66
Volume331,810
Avg. Volume801,643
Market Cap1.009B
Beta (3Y Monthly)2.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Coherus (CHRS) Catches Eye: Stock Jumps 6.9%
    Zacks14 days ago

    Coherus (CHRS) Catches Eye: Stock Jumps 6.9%

    Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Why Sony, AMC Entertainment Holdings, and Coherus BioSciences Jumped Today
    Motley Fool15 days ago

    Why Sony, AMC Entertainment Holdings, and Coherus BioSciences Jumped Today

    Guess which of these stocks could see big changes ahead.

  • Here's Why Coherus BioSciences Popped Today
    Motley Fool15 days ago

    Here's Why Coherus BioSciences Popped Today

    The biosimilar leader announced preliminary sales data for its most important product.

  • Read This Before Buying Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares
    Simply Wall St.16 days ago

    Read This Before Buying Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip sid...

  • Markitlast month

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    Coherus BioSciences Inc NASDAQ NMS:CHRSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | PositiveShort interest is moderate for CHRS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on March 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CHRS are favorable, with net inflows of $1.69 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CHRS earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 Coherus BioSciences Inc Earnings Call

  • Coherus BioSciences Inc (CHRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Coherus BioSciences Inc (CHRS) Q4 2018 Earnings Conference Call Transcript

    CHRS earnings call for the period ending December 31, 2018.

  • Here's Why Coherus BioSciences Rose 48.7% in January
    Motley Fool2 months ago

    Here's Why Coherus BioSciences Rose 48.7% in January

    The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.

  • Coherus BioSciences, Inc. (NASDAQ:CHRS) Is Expected To Breakeven
    Simply Wall St.3 months ago

    Coherus BioSciences, Inc. (NASDAQ:CHRS) Is Expected To Breakeven

    Coherus BioSciences, Inc.'s (NASDAQ:CHRS): Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The US$590m market-cap posted a loss in its most recent financial year of Read More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CHRS earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Coherus BioSciences Inc Earnings Call

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CHRS earnings conference call or presentation 10-May-18 8:30pm GMT

    Q1 2018 Coherus BioSciences Inc Earnings Call

  • Should You Buy Coherus Biosciences Inc (CHRS)?
    Insider Monkey4 months ago

    Should You Buy Coherus Biosciences Inc (CHRS)?

    Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]

  • Coherus BioSciences (CHRS): Moving Average Crossover Alert
    Zacks5 months ago

    Coherus BioSciences (CHRS): Moving Average Crossover Alert

    Coherus BioSciences, Inc. (CHRS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • Is Coherus BioSciences Inc’s (NASDAQ:CHRS) CEO Paid Enough Relative To Peers?
    Simply Wall St.5 months ago

    Is Coherus BioSciences Inc’s (NASDAQ:CHRS) CEO Paid Enough Relative To Peers?

    Denny Lanfear became the CEO of Coherus BioSciences Inc (NASDAQ:CHRS) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...

  • Reuters5 months ago

    Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount

    Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call.

  • Associated Press5 months ago

    Coherus BioSciences: 3Q Earnings Snapshot

    On a per-share basis, the Redwood City, California-based company said it had a loss of 87 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...